On March 8, 2018 Pantarhei Bioscience participated in a scientific symposium entitled Estetrol and Breast Cancer. The lectures were presented by Richard J. Santen (Estetrol in animal in vivo studies), Risto Erkkola (Estetrol in ex vivo explant cultures of human breast cancer tissue) and Herjan Coelingh Bennink (Estetrol treatment of advanced breast cancer). The symposium was chaired by Ludwig Kiesel and Herjan Coelingh Bennink.
On Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink lectured during the session: Breast cancer risk from hormonal treatment.
The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”.
For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer
The first patient has been enrolled in the Phase I/II clinical trial assessing safety and efficacy of estetrol (E4) in postmenopausal women with advanced ER+ breast cancer. The study is a multi-center, open-label, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of E4 for the treatment of patients with advanced breast cancer. In total 9-18 patients will be enrolled at three centers in Germany.
The main objectives of this study are to evaluate the safety, the effects on estrogen deficiency symptoms and the preliminary anti-tumor activity of E4 in patients with advanced breast cancer.